Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
US9862746B2 · kind B2 · utility
1Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2014 |
| Grant date | Jan 9, 2018 |
| Priority date | — |
| Expiry date | Mar 30, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.